Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden
- PMID: 37594381
- DOI: 10.1111/apt.17675
Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden
Abstract
Background: Inflammatory bowel disease has been linked to increasing healthcare costs, but longitudinal data on other societal costs are scarce.
Aim: To assess costs, including productivity losses, in patients with prevalent Crohn's disease (CD) or ulcerative colitis (UC) in Sweden between 2007 and 2020.
Methods: We linked data from national registers on all patients with CD or UC and a matched (sex, birthyear, healthcare region and education) reference population. We assessed mean costs/year in Euros, inflation-adjusted to 2020, for hospitalisations, out-patient visits, medications, sick leave and disability pension. We defined excess costs as the mean difference between patients and matched comparators.
Results: Between 2007 and 2020, absolute mean annual societal costs in working-age (18-64 years) individuals decreased by 17% in CD (-24% in the comparators) and by 20% in UC (-27% in comparators), due to decreasing costs from sick leave and disability, a consequence of stricter sick leave regulations. Excess costs in 2007 were dominated by productivity losses. In 2020, excess costs were mostly healthcare costs. Absolute and excess costs increased in paediatric and elderly patients. Overall, costs for TNF inhibitors/targeted therapies increased by 274% in CD and 638% in UC, and the proportion treated increased from 5% to 26% in CD, and from 1% to 10% in UC.
Conclusion: Between 2007 and 2020, excess costs shifted from productivity losses to direct healthcare costs; that is, the patients' compensation for sickness absence decreased, while society increased its spending on medications. Medication costs were driven both by expanding use of TNF inhibitors and by high costs for newer targeted therapies.
© 2023 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Comment in
-
Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expenses.Aliment Pharmacol Ther. 2023 Oct;58(8):832-833. doi: 10.1111/apt.17683. Aliment Pharmacol Ther. 2023. PMID: 37768289 No abstract available.
References
REFERENCES
-
- Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014;146(1):110-118.e3.
-
- Costa J, Magro F, Caldeira D, Alarcao J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19(10):2098-2110.
-
- Murthy SA-O, Begum J, Benchimol EA-O, Bernstein CN, Kaplan GA-O, McCurdy JD, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2020;69:274-282.
-
- Jeuring SF, Bours PH, Zeegers MP, Ambergen TW, van den Heuvel TR, Romberg-Camps MJ, et al. Disease outcome of ulcerative colitis in an era of changing treatment strategies: results from the Dutch population-based IBDSL cohort. J Crohns Colitis. 2015;9(10):837-845.
-
- Jeuring SF, van den Heuvel TR, Liu LY, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, et al. Improvements in the long-term outcome of Crohn's disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort. Am J Gastroenterol. 2017;112(2):325-336.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources